Cited by 1,616Neuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 556 of the 556 references it cites were found in a registry or an index; 25 of the 482 sources its claims cite were checked for support.

Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets

Open access
Gao, Chao, Jiang, Jingwen, Tan, Yuyan, Chen, Shengdi·2023·Signal Transduction and Targeted Therapy

Abstract

Microglia activation is observed in various neurodegenerative diseases. Recent advances in single-cell technologies have revealed that these reactive microglia were with high spatial and temporal heterogeneity. Some identified microglia in specific states correlate with pathological hallmarks and are associated with specific functions. Microglia both exert protective function by phagocytosing and clearing pathological protein aggregates and play detrimental roles due to excessive uptake of protein aggregates, which would lead to microglial phagocytic ability impairment, neuroinflammation, and eventually neurodegeneration. In addition, peripheral immune cells infiltration shapes microglia into a pro-inflammatory phenotype and accelerates disease progression. Microglia also act as a mobile vehicle to propagate protein aggregates. Extracellular vesicles released from microglia and autophagy impairment in microglia all contribute to pathological progression and neurodegeneration. Thus, enhancing microglial phagocytosis, reducing microglial-mediated neuroinflammation, inhibiting microglial exosome synthesis and secretion, and promoting microglial conversion into a protective phenotype are considered to be promising strategies for the therapy of neurodegenerative diseases. Here we comprehensively review the biology of microglia and the roles of microglia in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies and Huntington’s disease. We also summarize the possible microglia-targeted interventions and treatments against neurodegenerative diseases with preclinical and clinical evidence in cell experiments, animal studies, and clinical trials.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review synthesizes the biology of microglia and their roles across nine neurodegenerative diseases, arguing that reactive microglia are highly heterogeneous and act as a "double-edged sword" that both clears and propagates pathological protein aggregates. It catalogs microglia-targeted therapeutic strategies with preclinical and clinical evidence, concluding that modulating neuroinflammation is the most widely pursued approach.

Key findings

  • Microglia are not a simple M1/M2 binary; single-cell technologies (scRNA-seq, snRNA-seq, CyTOF) have identified disease-specific states such as disease-associated microglia (DAMs) localized near Aβ plaques in AD, and distinct Aβ- and tau-associated signatures in patients.
  • Microglia both protect and harm: they phagocytose Aβ, tau, α-syn, and TDP-43, but excessive uptake impairs phagocytosis and triggers neuroinflammation; microglia also propagate pathology as mobile vehicles and via exosomes (e.g., MGnD microglia hypersecrete pTau-containing EVs).
  • TREM2 is a central node: the R47H variant confers a 2- to 4-fold increased AD risk, and TREM2 p.R47H is a risk factor for FTD (OR = 5.06; p = 0.001); TREM2 effects on tau differ by disease stage.
  • Clinical translation is mixed: minocycline reduced microglial activation on PET in MSA but showed no clinical benefit (NCT00146809) and had harmful effects in ALS (NCT00047723); verdiperstat improved clinical scores and reduced neuroinflammation in a 12-week phase 2 MSA trial (NCT02388295); IONIS-HTTRx produced a 40% reduction in CSF mHTT at the two highest doses.

Methods

Narrative review; no primary data collection or meta-analysis. The authors synthesize mechanistic, preclinical (cell and mouse model), and clinical trial evidence across AD, PD, MSA, ALS, FTD, PSP, CBD, DLB, and HD, and compile a table of interventions with mouse-model findings and trial design, sample size, duration, and outcomes.

Limitations

The paper states that microglial heterogeneity and dynamics during disease progression still need to be better clarified, and that it is beyond its scope to thoroughly review all progress in microglial research. Evident from the text: many mechanistic conclusions rest on mouse models and postmortem tissue, and the authors repeatedly note unresolved questions (e.g., whether early microglial activation in DLB is protective or deleterious, and whether microglial activation in MSA is secondary to α-syn aggregation or neuronal loss). Several cited trials are listed as ongoing, recruiting, or completed without posted results, so their outcomes are not yet evaluable.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01588-0

Cites

556 of 556 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Effect of microglia on Aβ and tau pathology in Alzheimer’s disease. Microglia phagocytose Aβ and tau, limit propagation of Aβ and tau pathology. Under pathological conditions, microglia could also accelerate Aβ and tau spreading and lead to neurodegeneration. a TREM2-dependent DAM limits tau seeding and spreading around plaques. b Reactive microglia drive tau spreading and toxicity by promoting neuroinflammation, such as activating NLRP3 inflammasome or inducing NF-kB signaling. Microglial autophagy deficiency leads to dysregulation of lipid metabolism, thus increasing intraneuronal tau pathology and its spreading. MGnD microglia, which is common in neurodegeneration, hypersecrete EVs containing pTau, accelerates tau propagation. c Microglia increase their expression of IL-3Rα after recognition of Aβ deposits. Astrocyte-derived IL-3 binds to the upregulated IL-3Rα in microglia, enhancing microglial migration toward Aβ deposits, and the clearance of Aβ aggregates. d TREM2 promotes the conversion of microglia to the DAM phenotype, and BACE-1 inhibition in microglia facilitates the microglia phenotype transition from homeostatic to DAM-1 signature. DAM and DAM-1 phenotypes enhance amyloid clearance. LC3-associated endocytosis (LANDO) in microglia facilitates Aβ receptor recycling, increases Aβ surface receptors, and thus promotes Aβ clearance. In contrast, the microglia with enhanced aerobic glycolysis, and NgR expression on microglia increased with aging inhibit the phagocytosis and clearance of Aβ. e Microglia facilitate Aβ spreading. Aβ induces immune system activation and the formation and release of ASC specks. After being released from microglia, ASC specks bind to and promote the cross-seeding of Aβ, leading to amyloid seeding and spreading. Created with https://BioRender.com
Fig. 1 Effect of microglia on Aβ and tau pathology in Alzheimer’s disease. Microglia phagocytose Aβ and tau, limit propagation of Aβ and tau pathology. Under pathological conditions, microglia could also accelerate Aβ and tau spreading and lead to neurodegeneration. a TREM2-dependent DAM limits tau seeding and spreading around plaques. b Reactive microglia drive tau spreading and toxicity by promoting neuroinflammation, such as activating NLRP3 inflammasome or inducing NF-kB signaling. Microglial autophagy deficiency leads to dysregulation of lipid metabolism, thus increasing intraneuronal tau pathology and its spreading. MGnD microglia, which is common in neurodegeneration, hypersecrete EVs containing pTau, accelerates tau propagation. c Microglia increase their expression of IL-3Rα after recognition of Aβ deposits. Astrocyte-derived IL-3 binds to the upregulated IL-3Rα in microglia, enhancing microglial migration toward Aβ deposits, and the clearance of Aβ aggregates. d TREM2 promotes the conversion of microglia to the DAM phenotype, and BACE-1 inhibition in microglia facilitates the microglia phenotype transition from homeostatic to DAM-1 signature. DAM and DAM-1 phenotypes enhance amyloid clearance. LC3-associated endocytosis (LANDO) in microglia facilitates Aβ receptor recycling, increases Aβ surface receptors, and thus promotes Aβ clearance. In contrast, the microglia with enhanced aerobic glycolysis, and NgR expression on microglia increased with aging inhibit the phagocytosis and clearance of Aβ. e Microglia facilitate Aβ spreading. Aβ induces immune system activation and the formation and release of ASC specks. After being released from microglia, ASC specks bind to and promote the cross-seeding of Aβ, leading to amyloid seeding and spreading. Created with https://BioRender.comCC BY · PubMed Central
Fig. 2 Dysfunctional microglia impair neuronal activity in Alzheimer’s disease. Dysfunctional microglia in AD promotes the clearance of synapses and PNNs and impairs neuronal plasticity and activity. a Microglia harboring an APOE4 allele shows altered cellular metabolism with increased intracellular and extracellular lipid accumulation. The extracellular lipid droplets directly decreased neuronal activity by increasing inward K+ currents. Microglia release Aβ-containing EVs and lead to synaptic dysfunction. Microglial phagocytosis of synapses is affected by astrocytes. Selective removal of astrocytic APOE4 decreases microglial phagocytosis of synaptic elements. b Fibrinogen leaks from the site of cerebrovascular damage into the brain and subsequently binds to the microglial surface receptor CD11b. The interaction of fibrinogen and CD11b mediates microglial activation and leads to spine loss. Microglia engulf perineuronal nets (PNN) and promote plaque-dependent PNN loss. Created with https://BioRender.com
Fig. 2 Dysfunctional microglia impair neuronal activity in Alzheimer’s disease. Dysfunctional microglia in AD promotes the clearance of synapses and PNNs and impairs neuronal plasticity and activity. a Microglia harboring an APOE4 allele shows altered cellular metabolism with increased intracellular and extracellular lipid accumulation. The extracellular lipid droplets directly decreased neuronal activity by increasing inward K+ currents. Microglia release Aβ-containing EVs and lead to synaptic dysfunction. Microglial phagocytosis of synapses is affected by astrocytes. Selective removal of astrocytic APOE4 decreases microglial phagocytosis of synaptic elements. b Fibrinogen leaks from the site of cerebrovascular damage into the brain and subsequently binds to the microglial surface receptor CD11b. The interaction of fibrinogen and CD11b mediates microglial activation and leads to spine loss. Microglia engulf perineuronal nets (PNN) and promote plaque-dependent PNN loss. Created with https://BioRender.comCC BY · PubMed Central
Fig. 3 α-syn resulting in microglial response in Parkinson’s disease. Microglia are activated by α-syn, which can be encountered through phagocytosis of synapses or exocytosis from neighboring neurons. Different forms of α-syn, including monomeric, oligomeric, and fibrillar, can be encountered as the disease progresses. The recognition, uptake, and phagocytosis of α-syn by microglia are dependent on the type of α-syn encountered and the involved receptors and proteins. α-syn has been shown to initiate a pro-inflammatory response by interacting with membrane receptors that activate NF-κB through various mediators and assemble the NLRP3 inflammasome, leading to the production of inflammatory mediators and free radicals. The CCL2-CCR2 axis is involved in the infiltration of monocytes into the inflamed brain. Upregulation and activation of CCR2 have been observed in PD mouse models and patients, indicating a potentially harmful role in infiltrating monocytes in PD. Local cytokine and tissue signals can then induce the transformation of monocytes to macrophages. These cascades also result in the proliferation and migration of microglia. Created with https://BioRender.com
Fig. 3 α-syn resulting in microglial response in Parkinson’s disease. Microglia are activated by α-syn, which can be encountered through phagocytosis of synapses or exocytosis from neighboring neurons. Different forms of α-syn, including monomeric, oligomeric, and fibrillar, can be encountered as the disease progresses. The recognition, uptake, and phagocytosis of α-syn by microglia are dependent on the type of α-syn encountered and the involved receptors and proteins. α-syn has been shown to initiate a pro-inflammatory response by interacting with membrane receptors that activate NF-κB through various mediators and assemble the NLRP3 inflammasome, leading to the production of inflammatory mediators and free radicals. The CCL2-CCR2 axis is involved in the infiltration of monocytes into the inflamed brain. Upregulation and activation of CCR2 have been observed in PD mouse models and patients, indicating a potentially harmful role in infiltrating monocytes in PD. Local cytokine and tissue signals can then induce the transformation of monocytes to macrophages. These cascades also result in the proliferation and migration of microglia. Created with https://BioRender.comCC BY · PubMed Central
Fig. 4 Microglial roles in the pathogenesis of multiple system atrophy. a α-syn can interact with microglial toll-like receptors (TLRs) and then was phagocytosed by microglia in an MSA mouse model. But excessive uptake of α-syn by microglia led to a significant decrease in the phagocytic ability of microglia, triggered an inflammatory response of microglia including NF-κB and NLRP3 inflammasome signaling activation, reactive oxygen species production, pro-inflammatory cytokines upregulation, and eventually induced neurodegeneration. Besides, CD4 and CD8 T cell depletion attenuated α-syn-induced inflammation and demyelination in MSA mice. b Microglia act as a mobile vehicle to propagate α-syn after phagocytosis of α-syn in MSA patients. An in vitro study showed the ability of microglia to transport α-syn distally was impaired when treated with Epothilone D, a natural product that can inhibit microtubule activity. Created with https://BioRender.com
Fig. 4 Microglial roles in the pathogenesis of multiple system atrophy. a α-syn can interact with microglial toll-like receptors (TLRs) and then was phagocytosed by microglia in an MSA mouse model. But excessive uptake of α-syn by microglia led to a significant decrease in the phagocytic ability of microglia, triggered an inflammatory response of microglia including NF-κB and NLRP3 inflammasome signaling activation, reactive oxygen species production, pro-inflammatory cytokines upregulation, and eventually induced neurodegeneration. Besides, CD4 and CD8 T cell depletion attenuated α-syn-induced inflammation and demyelination in MSA mice. b Microglia act as a mobile vehicle to propagate α-syn after phagocytosis of α-syn in MSA patients. An in vitro study showed the ability of microglia to transport α-syn distally was impaired when treated with Epothilone D, a natural product that can inhibit microtubule activity. Created with https://BioRender.comCC BY · PubMed Central
Fig. 5 Microglial roles in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. a TDP-43 could be released into the extracellular matrix via exosomes or cell death. TDP-43 interacted with microglial TREM2 and then increased their phagocytosis and clearance by microglia. Phagocytosis of TDP43 aggregates by microglia led to microglial activation, microglial NLRP3 inflammasome activation, and pro-inflammatory markers upregulation, which have neurotoxic effects on motor neurons. Besides, progranulin deficiency in microglia activated microglial NF-κB signaling and promoted the release of pro-inflammatory cytokines, leading to hyperexcitability of medium spiny neurons. b Homeostatic microglia are protective against ALS. Progranulin deficiency aggravated TDP-43 pathology, promoted synaptic pruning by microglia, and led to synaptic loss and neurodegeneration. Progranulin deficiency also led to microglial lysosomal dysfunction and reduced myelin debris degradation, leading to the accumulation of myelin debris in white matter. Besides, C9orf72 loss of function promoted microglial gene signature transition from a homeostatic to an inflammatory state and promoted synaptic pruning by microglia and synapse loss in neurons. c At the early stage of the ALS mouse model (SOD1 mice), the anti-inflammatory cytokine IL-10 was upregulated in microglia, and microglia presented with an anti-inflammatory phenotype, which was neuroprotective to motor neurons. But at the late stage, microglia presented with a pro-inflammatory phenotype, which was neurotoxic to motor neurons. d Peripheral nerve reactive macrophages along peripheral axons of motor neurons were activated in an ALS mouse model (SOD1 mutant mice). Replacing peripheral nerve macrophages at disease onset reduced microglial pro-inflammatory responses and prolonged survival in these mice. NK cell infiltration into the cerebral motor cortex and spinal cord was observed in an ALS mouse model (SOD1G93A). NK cell depletion induced a protective microglial phenotype and increased survival in these mice. Created with https://BioRender.com
Fig. 5 Microglial roles in the pathogenesis of amyotrophic lateral sclerosis and frontotemporal dementia. a TDP-43 could be released into the extracellular matrix via exosomes or cell death. TDP-43 interacted with microglial TREM2 and then increased their phagocytosis and clearance by microglia. Phagocytosis of TDP43 aggregates by microglia led to microglial activation, microglial NLRP3 inflammasome activation, and pro-inflammatory markers upregulation, which have neurotoxic effects on motor neurons. Besides, progranulin deficiency in microglia activated microglial NF-κB signaling and promoted the release of pro-inflammatory cytokines, leading to hyperexcitability of medium spiny neurons. b Homeostatic microglia are protective against ALS. Progranulin deficiency aggravated TDP-43 pathology, promoted synaptic pruning by microglia, and led to synaptic loss and neurodegeneration. Progranulin deficiency also led to microglial lysosomal dysfunction and reduced myelin debris degradation, leading to the accumulation of myelin debris in white matter. Besides, C9orf72 loss of function promoted microglial gene signature transition from a homeostatic to an inflammatory state and promoted synaptic pruning by microglia and synapse loss in neurons. c At the early stage of the ALS mouse model (SOD1 mice), the anti-inflammatory cytokine IL-10 was upregulated in microglia, and microglia presented with an anti-inflammatory phenotype, which was neuroprotective to motor neurons. But at the late stage, microglia presented with a pro-inflammatory phenotype, which was neurotoxic to motor neurons. d Peripheral nerve reactive macrophages along peripheral axons of motor neurons were activated in an ALS mouse model (SOD1 mutant mice). Replacing peripheral nerve macrophages at disease onset reduced microglial pro-inflammatory responses and prolonged survival in these mice. NK cell infiltration into the cerebral motor cortex and spinal cord was observed in an ALS mouse model (SOD1G93A). NK cell depletion induced a protective microglial phenotype and increased survival in these mice. Created with https://BioRender.comCC BY · PubMed Central
Fig. 6 Possible microglia-targeted interventions and treatments against neurodegenerative diseases. Proof-of-principle therapeutic strategies used in cell experiments, animal studies, and clinical trials are shown together. Regulation of neuroinflammation, inhibition of microglial exosome synthesis and secretion, altering microglial metabolism, altering the microglial phenotype, and TREM2 activation are potential therapeutic strategies in treating neurodegenerative diseases. Among these, modulating neuroinflammation is the most widely used therapeutic target
Fig. 6 Possible microglia-targeted interventions and treatments against neurodegenerative diseases. Proof-of-principle therapeutic strategies used in cell experiments, animal studies, and clinical trials are shown together. Regulation of neuroinflammation, inhibition of microglial exosome synthesis and secretion, altering microglial metabolism, altering the microglial phenotype, and TREM2 activation are potential therapeutic strategies in treating neurodegenerative diseases. Among these, modulating neuroinflammation is the most widely used therapeutic targetCC BY · PubMed Central

Verification

Claims the paper makes

332 Not checked yet · 72 Own interpretation · 9 No basis given · 8 Supported · 7 Partly supported · 3 Supported so far · accuracy not yet measured

Verify all 457 references — free account

Show all 227 claims

  • It may state two separate claims as one. 186
  • Probably not a substantial claim. 23
204 of 204
  • The authors state this as an assumption.

    The M1/M2 and A1/A2 classifications, although inaccurate, are helpful for elucidating microglia-astrocyte interaction.

    “Although the canonical M1/M2 (microglia) and A1/A2 (astrocyte) classifications are not accurate in describing the states of microglia and astrocytes, this classification is helpful to elucidate the interaction of microglia and astrocytes and will be adopted here.”
  • The paper relies on this without support.

    Increases in TSPO-PET ligand binding in AD and PD brains reflect microglial activation.

    “Consistent evidence using PET imaging indicated microglial activation in the brains of AD patients.”
    “Additionally, PET scans of PD patients revealed widespread microglial activation.”
  • The paper relies on this without support.

    Findings from animal models of neurodegenerative diseases can be extrapolated to human disease mechanisms.

    “Transgenetic mouse models of MSA overexpressing α-syn in oligodendrocytes also presented early and significant microglial activation and related neuroinflammation accompanying the α-syn accumulation in oligodendrocytes.292,293”
  • The paper relies on this without support.

    Findings from animal models of neurodegenerative diseases are relevant to human disease.

    “These findings suggest that modulation of microglial bioenergetic pathways and metabolic state might be promising strategies to treat AD.”
  • The paper relies on this without support.

    Microglial activation observed by PET or immunohistochemistry reflects functional microglial state.

    “In vivo brain imaging allows the investigation of inflammatory processes in the early stages of the disease and facilitates longitudinal monitoring of microglial activation during disease progression.”
  • The paper relies on this without support.

    Modulating microglial phenotype or reducing neuroinflammation will be safe and effective in humans.

    “The above evidence suggests that modulating microglia-mediated neuroinflammation is a key therapeutic target in treating AD.”
  • The paper relies on this without support.

    The M1/M2 polarization classification is valid and meaningful for microglia.

    “Furthermore, stimulation of CB1 and/or CB2 receptors in microglia was demonstrated to induce M2 polarization, while knocking out CB2 receptors in mice inhibited M2 polarization.”
  • The paper relies on this without support.

    Exosome-mediated tau propagation is a significant mechanism in human tauopathies.

    “Overall, microglia and their secreted exosomes contribute to tauopathy progression and the inhibition of exosome synthesis or secretion could be a therapeutic target.”
  • The paper relies on this without support.

    Heterozygous GRN mutations cause progranulin haploinsufficiency, resulting in patients with FTD (FTD-GRN).

    “Heterozygous GRN mutations cause progranulin haploinsufficiency, resulting in patients with FTD (FTD-GRN).”
  • The paper relies on this without support.

    GRN encodes a secreted protein (progranulin) expressed in microglia and neurons in human brains.

    “GRN encodes a secreted protein (progranulin) expressed in microglia and neurons in human brains.”
  • The paper relies on this without support.

    There is no disease-modifying therapy for HD, so current treatment focuses on chorea and mental symptoms.

    “There is no disease-modifying therapy for HD, so current treatment focuses on chorea and mental symptoms.”
  • The paper relies on this without support.

    GWAS have demonstrated that most AD risk genes were highly or exclusively in microglia.

    “Recently, GWAS have demonstrated that most AD risk genes were highly or exclusively in microglia, suggesting that microglia play an important role in the development of AD.”
12 of 12

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

4 retracted

Items 201–400 of 556

Research works printed but not linked: 4

  1. Rı´o-Hortega, P. El “Tercer Elemento” de los Centros Nerviosos. I. La Microglı´a en Estado Normal, Boletı´n de la Sociedad Espan˜ola de Biologı´a VIII, pp. 67–82, (in Spanish). (1919).
  2. Rı´o-Hortega, P. El “Tercer Elemento de los Centros Nerviosos”. II. Intervencio´n de la Microglı´a en los Procesos Patolo´gicos (Ce´lulas en Bastoncitoy Cuerpos Gra´nuloadiposos), Boletı´n de la Sociedad Espan˜ ola de Biologı´a VIII, pp. 91–103, (in Spanish). (1919).
  3. Rı´o-Hortega, P. El “Tercer Elemento” de los Centros Nerviosos. III. Naturaleza Probable de la Microglı´a, Boletı´n de la Sociedad Espan˜ ola de Biologı´a VIII, pp. 108–121, (in Spanish). (1919).
  4. Rı´o-Hortega, P. El “Tercer Elemento de los Centros Nerviosos”. IV. Poder Fagocitarioy Movilidad de la Microglı´a, Boletı´n de la Sociedad Espan˜ ola de Biologı´a VIII, pp. 154–171, in Spanish. (1919).

Cited by

Sorted by citations

See all 1,616

Metadata

Authors
Gao, C., Jiang, J., Tan, Y., & Chen, S.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Tan, Yuyan
  • Chen, Shengdi
Venue
Signal Transduction and Targeted Therapy
Published
2023-09-22
Volume
8
Issue
1
Pages
359-359
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4386913845
Cited by
1,616
References
556
Citations by year
2026: 656 · 2025: 672 · 2024: 280 · 2023: 8
FWCI
42.17
Type
journal article
Language
en
Open access
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (2017-01-07-00-01-E00046, 2018SHZDZX05, 81971183, 201701, 82101477, 81971187, 82171401)
  • Shanghai Municipal Education Commission (2017-01-07-00-01-E00046, 81971187, 2018SHZDZX05)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
microglia, neurodegenerative diseases, microglial activation, microglial heterogeneity, phagocytosis, protein aggregate clearance, neuroinflammation, peripheral immune cell infiltration, extracellular vesicles, autophagy, microglia-targeted therapy, Alzheimer's disease, Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, Huntington's disease
MeSH terms
Neuroinflammatory Diseases, Alzheimer Disease, Animals, Microglia, Neurodegenerative Diseases, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review